Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q2 2024 ▲▼ | Q3 2024 ▲▼ | Change ▲▼ | Q2 2024 ▲▼ | Q3 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Liquidia Corporation(LQDA) | 10,360,945 | 8,118,592 | -2,242,353 | $124.33M | $81.19M | 25.73% | -$43.15M |
| Verona Pharma PlcADS | 1,843,756 | 1,436,878 | -406,878 | $26.66M | $41.34M | 13.10% | +$14.68M |
| Exelixis, Inc.(EXEL) | 1,525,730 | 1,525,730 | 0 | $34.28M | $39.59M | 12.55% | +$5.31M |
| Evolus, Inc.(EOLS) | 2,167,790 | 2,193,488 | +25,698 | $23.52M | $35.53M | 11.26% | +$12.01M |
| Anika Therapeutics Inc | 1,435,993 | 1,435,130 | -863 | $36.37M | $35.45M | 11.24% | -$926.0K |
| Agios Pharmaceuticals, Inc.(AGIO) | 514,711 | 579,717 | +65,006 | $22.19M | $25.76M | 8.16% | +$3.56M |
| BioCryst Pharmaceuticals, Inc.(BCRX) | 4,598,737 | 2,583,585 | -2,015,152 | $28.42M | $19.64M | 6.22% | -$8.78M |
| Y-Mabs Therapeutics Inc | 582,078 | 1,195,253 | +613,175 | $7.03M | $15.72M | 4.98% | +$8.69M |
| Mineralys Therapeutics, Inc.(MLYS) | 745,758 | 981,155 | +235,397 | $8.73M | $11.88M | 3.77% | +$3.16M |
| NovaBridge BiosciencesADS(NBP) | 3,374,791 | 3,499,330 | +124,539 | $5.64M | $4.34M | 1.38% | -$1.30M |
| Enanta Pharmaceuticals, Inc.(ENTA) | 1,042,889 | 322,453 | -720,436 | $13.53M | $3.34M | 1.06% | -$10.19M |
| Outlook Therapeutics, Inc.(OTLK) | 500,000 | 318,699 | -181,301 | $3.69M | $1.70M | 0.54% | -$1.99M |
| Alimera Sciences Inc | 16,835,154 | 0 | -16,835,154 | $93.60M | $0 | — | -$93.60M |